Abacus Life, Inc. (NASDAQ:ABL - Get Free Report) has received an average recommendation of "Moderate Buy" from the six research firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $13.1250.
Several research firms have commented on ABL. Wall Street Zen upgraded shares of Abacus Life from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Abacus Life in a report on Wednesday. Finally, Piper Sandler reduced their price objective on Abacus Life from $12.00 to $10.00 and set an "overweight" rating on the stock in a research note on Wednesday, July 2nd.
View Our Latest Stock Report on ABL
Institutional Trading of Abacus Life
Institutional investors have recently bought and sold shares of the stock. AlphaQuest LLC purchased a new position in Abacus Life during the second quarter worth $25,000. Darwin Wealth Management LLC bought a new stake in shares of Abacus Life in the 2nd quarter worth about $27,000. Raymond James Financial Inc. bought a new stake in shares of Abacus Life in the 2nd quarter worth about $34,000. Legal & General Group Plc purchased a new position in shares of Abacus Life during the 2nd quarter worth about $34,000. Finally, KLP Kapitalforvaltning AS bought a new position in Abacus Life during the 2nd quarter valued at about $41,000.
Abacus Life Stock Performance
NASDAQ:ABL opened at $5.96 on Thursday. The company has a debt-to-equity ratio of 0.57, a current ratio of 0.76 and a quick ratio of 0.76. Abacus Life has a 1 year low of $4.60 and a 1 year high of $10.30. The stock's 50 day simple moving average is $6.26 and its two-hundred day simple moving average is $6.66. The company has a market cap of $576.69 million, a price-to-earnings ratio of -99.33 and a beta of -0.01.
Abacus Life (NASDAQ:ABL - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.22 EPS for the quarter, beating analysts' consensus estimates of $0.16 by $0.06. Abacus Life had a positive return on equity of 17.65% and a negative net margin of 0.72%.The firm had revenue of $56.23 million during the quarter, compared to the consensus estimate of $43.38 million. As a group, equities analysts anticipate that Abacus Life will post 0.62 earnings per share for the current fiscal year.
About Abacus Life
(
Get Free Report)
Abacus Life, Inc operates as an alternative asset manager specializing in life insurance products. It purchases life insurance policies from consumers seeking liquidity and manages policies over time via trading, holding, and/or servicing. The company was founded in 2004 and is based in Orlando, Florida.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Abacus Life, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abacus Life wasn't on the list.
While Abacus Life currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.